MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

Osiris Therapeutics Inc.

Smith & Nephew closes Osiris Therapeutics, Leaf Healthcare buys

By

Smith & Nephew (NYSE:SNN) said today that it closed both its $660 million acquisition of Osiris Therapeutics (NSDQ:OSIR) and its purchase of Leaf Healthcare and its Leaf Patient Monitoring System. The London-based company said that it paid $19 per share in cash for Osiris, which develops and produces regenerative medicine products including skin, bone grafts and articular […]

Osiris shareholders sue to block $660m merger with Smith & Nephew

By

A group of Osiris Therapeutics (NSDQ:OSIR) shareholders is suing to block its $660 million acquisition by Smith & Nephew (NYSE:SNN) because the purchase price is too low. Earlier this month the British orthopedics and wound care giant put $19 per share on the table to acquire Osiris and its regenerative medicine portfolio, representing a 37% premium on the 90-day […]

Smith & Nephew puts up $660m for Osiris Therapeutics

By

Smith & Nephew (NYSE:SNN) said today that it agreed to put $660 million on the table to acquire Osiris Therapeutics (NSDQ:OSIR) and its regenerative medicine portfolio. The British orthopedics and wound care giant said the $19-per-share deal is a 37% premium on the 90-day volume-weighted average for OSIR shares. It’s structured as a two-step tender […]

MiMedx escapes Osiris trade theft suit

By

MiMedx (NSDQ:MDXG) enjoyed a rare spot of good news when a federal judge in Maryland this week dismissed a trade theft and breach-of-contract lawsuit brought by Osiris Therapeutics over MiMedx’s  Stability Biologics acquisition. Columbia, Md.-based Osiris said it inked a distribution deal back in 2013 to have Stability sell a pair of its products through the end of 2015. But after […]

Osiris levels $7m trade theft, breach-of-contract suit against MiMedx over Stability Biologics deal

By

Osiris Therapeutics leveled trade theft and breach-of-contract charges worth nearly $7 million against a regenerative medicine rival, stemming from the Stability Biologics acquisition by MiMedx (NSDQ:MDXG). Columbia, Md.-based Osiris said it inked a distribution deal back in 2013 to have Stability sell a pair of its products through the end of 2015. But after MiMedx paid $10 million for […]

Osiris wins positive review from BCBSA for Grafix

By

Osiris Therapeutics said today the Blue Cross Blue Shield Association gave the company’s Grafix a positive review when used to treat individuals with diabetic lower-extremity ulcers. Gravix is a cryopreserved placental membrane designed as a wound cover for patients with chronic wounds, and can conform and be applied directly to acute and chronic wounds, the company […]